Prof Dr. Baohui Han - Medicine - Excellence in Research

Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine - China

AUTHOR PROFILE

EARLY ACADEMIC PURSUITS

Dr. Han Baohui embarked on his academic journey with a focus on respiratory medicine, laying the groundwork for his illustrious career. His dedication to the field led him to pursue specialized training and qualifications, setting the stage for his impactful contributions in clinical research.

PROFESSIONAL ENDEAVORS

Dr. Han's professional trajectory is marked by leadership roles and pioneering contributions in respiratory medicine. As a Professor at the Shanghai Chest Hospital and Vice-president, he has played a pivotal role in shaping clinical practices and research initiatives. Notably, his appointment as Chief of the Pulmonary Department underscores his expertise and authority in the field.

CONTRIBUTIONS AND RESEARCH FOCUS ON MEDICINE

Dr. Han's research focus revolves around the clinical transformation of lung tumors, with a particular emphasis on lung cancer biological immune targeted therapy and the clinical study of new antitumor drugs. His involvement as a Principal Investigator (PI) or participant in numerous international multicenter clinical trials reflects his commitment to advancing treatment modalities and improving patient outcomes.

IMPACT AND INFLUENCE

Dr. Han's influence extends beyond his clinical practice, with his research garnering international recognition and acclaim. His leadership as a PI in groundbreaking clinical trials, such as Anlotinib for non-small cell lung cancer and bevacizumab, Medicine underscores his significant contributions to the field of oncology.

ACADEMIC CITES

Acknowledging his expertise and contributions, Dr. Han has received several prestigious awards, including the "China Medical Science and Technology Award" and the "Shanghai Medical Science Award." These accolades serve as a testament to his impact Medicine on advancing medical knowledge and improving patient care.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Han's legacy is characterized by his relentless pursuit of innovation and excellence in respiratory medicine. His leadership roles in various medical associations and societies, coupled with his extensive involvement in clinical research, position him as a key figure in shaping the future of lung cancer treatment. Moving forward, Dr. Han's continued dedication to advancing clinical practice and research will undoubtedly leave a lasting impact on the field.

NOTABLE PUBLICATIONS

Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer 2024

Physicians’ Knowledge of Pulmonary Rehabilitation in China: A Cross-Sectional Study 2024

Schwann cell-derived exosomes promote lung cancer progression via miRNA-21-5p 2024

Rationale and design of a multicenter, randomized phase II trial of durvalumab 2023

Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms 2023

EARLY ACADEMIC PURSUITS:

Rakhat Akmatova embarked on her academic journey, culminating in a Master's in Public Health from Roehampton University, London, UK, in 2017. Prior to this, she pursued a BMBS (honors degree) in "Medical Care" at the School of Medicine, Kyrgyz-Russian Slavic University, Bishkek, Kyrgyzstan, where she laid the foundation for her medical expertise.

PROFESSIONAL ENDEAVORS:

Akmatova's professional trajectory includes a postgraduate certificate in "Surgery" specialization during her clinical residency at the Medical Faculty, Kyrgyz-Russian Slavic University. She further honed her skills through a 10-month certificate program in "Public Health Policy and Management" at Emory University, Atlanta, GA, USA. Her commitment to research is evident in the certificate program focused on the study of HIV infection in Hannover, Germany.

CONTRIBUTIONS AND RESEARCH FOCUS ON PUBLIC HEALTH

Rakhat Akmatova has made substantial contributions in the field of public health. Her involvement in the Hubert H. Humphrey Fellowship program attests to her dedication to learning and leadership. Notably, she actively participated in initiatives addressing the opioid crisis in the USA and underwent training in quality improvement with a "Lean Six Sigma" yellow belt from TUM, Munich, Germany.